Management of tuberculosis in children and new treatment options

Infectious Disorders - Drug Targets

Volumn 11, Issue 2, 2011, Pages 144-156

  Marais, B J ^a   Schaaf, H S ^a   Donald, P R ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Management; Pediatric tuberculosis; Treatment

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; PNU 100480; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTHRALGIA; ARTICLE; CHILDHOOD DISEASE; CONFUSION; CONVULSION; DEPRESSION; DIARRHEA; DOSE CALCULATION; DRUG FORMULATION; DRUG TREATMENT FAILURE; EXTENSIVE DRUG RESISTANCE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; INFECTION PREVENTION; INSOMNIA; MIXED INFECTION; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PSYCHOSIS; RECOMMENDED DRUG DOSE; SECRETION DISCOLORATION; TOXICITY; TUBERCULOSIS; VISUAL IMPAIRMENT; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 79954537609     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152611795589645     Document Type: Article

References (114)

1. Nelson, L.J.; Wells, C.D. Global epidemiology of childhood tuberculosis. Int. J. Tuberc. Lung Dis. 2004, 8, 636-647.
2. World Health Organization. Global tuberculosis control 2010. WHO Report [Online]2010. http,//www.who.int/tb/publications/globalreport/2010/gtbr10_main.pdf (Accessed January 17, 2011)
3. Newton, S.M.; Brent, A.J.; Anderson, S.; Whittaker, E.; Kampmann, B. Paediatric tuberculosis. Lancet Infect. Dis.; 2008, 8, 499-510.
4. Marais B.J.; Hesseling, A.C.; Gie, R.P.; Schaaf, H.S.; Beyers, N. The burden of childhood tuberculosis and the accuracy of routine surveillance data in a high-burden setting. Int. J. Tuberc. Lung Dis., 2006, 10, 259-263.
5. Webb, E.A.; Hesseling, A.C.; Schaaf, H.S.; Gie, R.P.; Lombard, C.J.; Spitaels, A.; Delport, S.; Marais, B.J.; Donald, K.; Hindmarsh, P.; Beyers, N. High prevalence of Mycobacterium tuberculosis infection and disease in children and adolescents with type 1 diabetes mellitus. Int. J. Tuberc. Lung Dis., 2009, 13, 868-874.
6. Donald, P.R. Childhood tuberculosis, the hidden epidemic. Int. J. Tuberc. Lung Dis. 2004, 8, 627-629.
7. Smith, R.C. Congenital tuberculosis, a rare manifestation of a common disease. Curr. Opin. Infect. Dis., 2002, 15, 269-274.
8. Marais, B.J.; Gie, R.P.; Schaaf, H.S.; Hesseling, A.C.; Enarson, D.A.; Beyers, N. The spectrum of childhood tuberculosis in a highly endemic area. Int. J. Tuberc. Lung Dis., 2006, 10, 732-738.
9. Chintu, C.; Mudenda, V.; Lucas, S.; Nunn, A.; Lishimpi, K.; Maswahu, D.; Kasolo, F.; Mwaba, P.; Bhat, G.; Terunuma, H.; Zumla, A.; UNZA-UCLMS Project Paediatric Post-mortem Study Group. Lung diseases at necropsy in African children dying from respiratory illnesses, a descriptive necropsy study. Lancet, 2002, 360, 985-990.
10. McNally, L.M.; Jeena, P.M.; Gajee, K.; Thula, S.A.; Sturm, A.W.; Cassol, S.; Tomkins, A.M.; Coovadia, H.M.; Goldblatt, D. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children, a prospective descriptive study. Lancet, 2007, 369, 1440-1451.
11. Marais, B.J.; Pai, M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr. Respir. Rev., 2007, 8, 124-133.
12. Marais, B.J.; Cotton, M.; Graham, S.; Beyers, N. Diagnosis and management challenges of childhood TB in the era of HIV. J. Infect. Dis., 2007, 196(Suppl 1), S76-S85.
13. Marais, B.J.; Schaaf, H.S.; Donald, P.R. Pediatric tuberculosis, Issues related to current and future treatment options. Future Microbiol., 2009, 4, 661-675.
14. Marais B.J.; Gie, R.P.; Schaaf, H.S.; Donald, P.R.; Beyers, N.; Starke, J. Childhood pulmonary tuberculosis-Old wisdom and new challenges. Am. J. Resp. Crit. Care Med., 2006, 173, 1078-1090.
15. Kruk, A.; Gie, R.P.; Schaaf, H.S.; Beyers, N.; Marais, B.J. Symptom-based screening of child tuberculosis contacts, improved feasibility in resource-limited settings. Pediatrics, 2008, 121, e1646-1652.
16. World Health Organization. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. WHO Report [Online].2010. http,//whqlibdoc.who.int/publications/2010/9789241500449_eng.pdf (Accessed January 17, 2011)
17. Balcells, M.E.; Thomas, S.L.; Godfrey-Faussett, P.; Grant, A.D. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg. Infect. Dis., 2006, 12, 744-751.
18. Marais, B.J.; Ayles, H.; Graham, S.M.; Godfrey-Faussett, P. Screening and preventive therapy for tuberculosis. Clin. Chest. Med., 2009, 30, 827-846.
19. The United States Public Health Service Tuberculosis Prophylaxis Trial collaborators. Prophylactic effects of isoniazid on primary tuberculosis in children. Am. Rev. Tuberc., 1957, 76, 942-963.
20. Smieja, M.J.; Marchettie, C.A.; Cook, D.J.; Smaill, F.M. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Library, 1999, 4, 1-20.
21. Lawn, S.D.; Bekker, L.G.; Middelkoop, K.; Myer, L.; Wood, R. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa, the need for age-specific interventions. Clin. Infect. Dis.; 2006, 42, 1040-1047.
22. Cotton, M.F.; Schaaf, H.S.; Lottering, G.; Wever, H.L.; Coetzee, J.; Nachman, S. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int. J. Tuberc. Lung Dis., 2008, 12, 225-227.
23. Zar, H.J.; Cotton, M.F.; Strauss, S.; Karpakis, J.; Hussey, G.; Schaaf, H.S.; Rabie, H.; Lombard, C.J. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV, randomized controlled trial BMJ, 2007, 334, e136.
24. th Conference on Retroviruses and Opportunistic Infections. Montreal, Feb 8-11, 2009 [0nline], Abstract #909. http,//www.retroconference.org/AbstractSearch/Default.aspx?Conf=18 (Accessed January 17, 2011)
25. Violari, A.; Cotton, M.F.; Gibb, D.M.; Babiker, A.G.; Steyn, J.; Madhi, S.A.; Jean-Philippe, P.; McIntyre J.A. CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med., 2008, 359, 2233-2244.
26. Golub, J.E. Saraceni, V.; Cavalcante, S.C.; Pacheco, A.G.; Moulton, L.H.; King, B.S.; Efron, A.; Moore, R.D.; Chaisson, R.E.; Durovni, B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS, 2007, 21, 1441-1448.
27. Golub, J.E.; Pronyk, P.; Mohapi, L.; Thsabangu, N.; Moshabela, M.; Struthers, H.; Gray, G.E.; McIntyre, J.A.; Chaisson, R.E.; Martinson, N.A. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa, a prospective cohort. AIDS, 2009, 23, 631-636.
28. Marais, B.J.; van Zyl, S.; Schaaf, H.S.; van Aardt, M.; Gie, R.P. Beyers, N. Adherence to isoniazid preventive chemotherapy in children, a prospective community based study. Arch. Dis. Child, 2006, 91, 762-765.
29. Van Zyl, S.; Marais, B.J.; Hesseling, A.C.; Gie, R.P.; Beyers, N.; Schaaf, H.S. Adherence to antituberculosis chemoprophylaxis and treatment in children. Int. J. Tuberc. Lung Dis., 2006, 10, 13-18.
30. Ormerod, L.P. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch. Dis. Child, 1998, 78(2), 169-171.
31. Ena, J.; Valls, V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection, a meta-analysis. Clin. Infect. Dis., 2005, 40, 670-676.
32. Spyridis, N.P.; Spyridis, P.G.; Gelesme, A.; Sypsa, V.; Valianatou, M.; Metsou, F.; Gourgiotis, D.; Tsolia, M.N. The effectiveness of a 9-month regimen of isoniazid alone versus 3-and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children, results of an 11-year randomized study. Clin. Infect. Dis., 2007, 45, 715-722.
33. Priest, D.H.; Vossel, L.F.; Sherfy, E.A.; Hoy, D.P.; Haley, C.A. Use of intermittent rifampin and pyrazinamide therapy for tuberculosis infection in a targeted tuberculin-testing program. Clin. Infect. Dis., 2004, 15, 1764-1771.
34. Magdorf, K.; Arizzi Rusche, AF, Geiter, R.J.; O'Brien, R.J.; Wahn, U. Compliance and tolerance of new antitubercular short-term chemopropreventive regimens in childhood-a pilot project. Pneumologie, 1994, 48(10), 761-764.
35. Donald, P.R.; Diacon, A.H. The early bactericidal activity of antituberculosis drugs, a literature review. Tuberculosis, 2008, 88(Suppl 1), S75-S83.
36. Mitchison, D.A. Role of individual drugs in the chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis., 2000, 4, 796-806.
37. Donald, P.R.; Schaaf, H.S. Old and new drugs for the treatment of tuberculosis in children. Paediatr. Respir. Rev., 2007, 8, 134-141.
38. Mitchison, D.A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis., 1998, 2, 10-15.
39. Volmink, J.; Garner, P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst. Rev., 2007, (4), CD003343.
40. Dutt, A.K.; Moers, D.; Stead, W.W. Smear and culture negative pulmonary tuberculosis, four month short course therapy. Am. Rev. Respir. Dis., 1989, 139, 867-870.
41. Johnson, J.L.; Hadad, D.J.; Dietze, R.; Maciel, E.L.; Sewali, B.; Gitta, P.; Okwera, A.; Mugerwa, R.D.; Alcaneses, M.R.; Quelapio, M.I.; Tupasi, T.E.; Horter, L.; Debanne, S.M.; Eisenach, K.D.; Boom, W.H. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am. J. Respir. Crit. Care Med., 2009, 180, 558-563.
42. Te Water Naude, JM, Donald, P.R.; Hussey, G.D.; Kibel, M.A.; Louw, A.; Perkins, D.R.; Schaaf, H.S. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatr. Infect. Dis. J., 2000, 19, 405-410.
43. Al-Dossary, F.S.; Ong, L.T.; Correa, A.G.; Starke, J.R. Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy. Pediatr. Infect. Dis. J., 2002, 21, 91-97.
44. Vernon, A.; Burman, W.; Benator, D.; Khan, A.; Bozeman, L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet, 1999, 353, 1843-1847.
45. Rieder, H.L.; Arnadottir, A.; Trebucq, A.; Enarson, D.A. Tuberculosis treatment, dangerous regimens? Int. J. Tuberc. Lung Dis., 2001, 5, 1-3.
46. Gie, R.P.; Matiru, R.H. Supplying quality-assured child-friendly anti-tuberculosis drugs to children. Int. J. Tuberc. Lung Dis., 2009, 13, 277-278.
47. Ellard, G.A.; Humphries, M.J.; Allen, B.W. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am. Rev. Respir. Dis., 1993, 148, 650-655.
48. Donald, P.R.; Seifert, H.I. Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis. J. Pediatr., 1989, 115, 483-486.
49. Donald, P.R.; Schoeman, J.F.; van Zyl, L.E.; De Villiers, J.N.; Pretorius, M.; Springer, P. Intensive short course chemotherapy in the management of tuberculous meningitis. Int. J. Tuberc. Lung Dis., 1998, 2, 704-711.
50. Alarcon, F.; Escalante, L.; Perez, Y.; Banda, H.; Chacon, G.; Duenas, G. Tuberculous meningitis, short course therapy. Arch. Neurol., 1990, 47, 1313-1317.
51. Schaaf, H.S.; Parkin, D.P.; Seifart, H.I.; Werely, C.J.; Hesseling, P.B.; van Helden, P.D.; Maritz, J.S.; Donald, P.R. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch. Dis. Child, 2005, 90, 614-618.
52. McIlleron, H.; Willemse, M.; Werely, C.J.; Hussey, G.D.; Schaaf, H.S.; Smith, P.J.; Donald, P.R. Isoniazid Plasma Concentrations in a Cohort of South African Children with Tuberculosis, Implications for International Pediatric Dosing Guidelines. Clin. Infect. Dis., 2009, 48, 1547-1553.
53. Schaaf, H.S.; Willemse, M.; Cilliers, K.; Labadarios, D.; Maritz, J.S.; Hussey, G.D.; McIlleron, H.; Smith, P.; Donald, P.R. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med,; 2009, 7(1), 19.
54. Graham, S.M.; Bell, D.J.; Nyirongo, S.; Hartkorn, R.; Ward, S.A.; Molyneux, E.M. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status and human immunodeficiency virus infection. Antimicrob. Agents Chemother., 2006, 50, 407-413.
55. Thee, S.; Detjen, A.; Wahn, U.; Magdorf, K. Pyrazinamide serum levels in childhood tuberculosis. Int. J. Tuberc. Lung Dis., 2008, 12, 1099-1101.
56. Thee, S.; Detjen, A.; Quarcoo, D.; Wahn, U.; Magdorf K. Ethambutol in paediatric tuberculosis, aspects of ethambutol serum concentration, efficacy and toxicity in children. Int. J. Tuberc. Lung Dis., 2007, 11, 965-71.
57. Donald, P.R.; Maher, D.; Maritz, J.S.; Qazi, S. Ethambutol dosage for the treatment of children, literature review and recommendations. Int. J. Tuberc. Lung Dis., 2006, 10, 1318-1330.
58. WHO Reports 2009 [Online]. http,//www.who.int/selection_medicines/committees/expert/17/WEB_TRS_DEC_2009.pdf (Accessed on January 17, 2011)
59. Rakesh, L.; Ramesh Menon, P.; Kabra, S.K. Concerns on the Dosing of Antitubercular Drugs for Children in RNTCP. Indian Pediatr., 2008, 45, 852-854.
60. Ormerod, L.P.; Skinner, C.; Wales, J. Hepatotoxicity of antituberculosis drugs. Thorax, 1996, 51, 111-113.
61. Donald, P.; Cilliers, K.; Willemse, M.; Labadarios, D.; Schaaf, H.; Maritz, J.; Werely C. Pyridoxine serum concentrations in children hospitalized with tuberculosis. Int. J. Tuberc. Lung Dis., 2007, 11(Suppl 1), S225.
62. Schaaf, H.S.; Krook, S.; Hollemans, D.W.; Warren, R.M.; Donald, P.R.; Hesseling, A.C. Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J., 2005, 24, 685-691.
63. Marais, B.J.; Rabie, H., Cotton, M.F. TB and HIV in children-advances in prevention and management. Paediatr. Respir. Rev., 2011, (1), 39-45.
64. Anonymous. Centers for Disease Control and Prevention. [Online] http,//www.cdc.gov/nchstp/tb/ (Accessed on January 18, 2010).
65. World Health Organization. Rapid advice, WHO Report [Online] 2009. Available, http,//www.who.int/hiv/pub/arv/advice/en/index.html (Accessed on January 18, 2011)
66. Gerstoft, J.; Kirk, O.; Obel, N.; Pedersen, C.; Mathiesen, L.; Nielsen, H.; Katzenstein, T.L.; Lundgren, J.D. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS, 2003, 17, 2045-2052.
67. th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, [Online] Feb 8-11, 2009, abstract #908. http,//www.retroconference.org/2009/Abstracts/34148.htm (Accessed January 17, 2011)
68. Ren, Y.; Nuttall, J.J.; Egbers, C.; Eley, B.S.; Meyers, T.M.; Smith, P.J.; Maartens, G.; McIlleron, H.M. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J. Acquir. Immune Defic. Syndr., 2008, 47, 566-569.
69. Chintu, C.; Bhat, G.J.; Walker, A.S. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP), a double-blind randomised placebo-controlled trial. Lancet, 2004, 364, 1865-71.
70. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults in resource-limited settings. World Health Organization Report, Geneva, [Online] 2006. http,//www.who.int/3by5/mediacentre/news32/en/index.html (Accessed on January 17, 2011)
71. Meintjes, G.; Lawn, S.D.; Scano, F.; Maartens, G.; French, M.A.; Worodria, W.; Elliott, J.H.; Murdoch, D.; Wilkinson, R.J.; Seyler, C.; John, L.; van der Loeff, M.S.; Reiss, P.; Lynen, L.; Janoff, E.N.; Gilks, C.; Colebunders R, International Network for the study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome, case definitions for use in resourcelimited settings. Lancet Infect. Dis., 2008, 8, 516-23.
72. Rabie, H.; Violari, A.; Madhi, S.; Gibb, D.; Steyn, J.; van Niekerk, R.; Josipovic, D.; Innes, S.; and Cotton, M. Complications of BCG Vaccination in HIV-infected and-uninfected Children, CHER Study. [Online] 15th Conference On Retroviruses and Opportunistic Infections (CROI). Boston, Mass February 3-6, 2008. http,//www.retroconference.org/2008/Abstracts/33235.htm (Accessed on January 17, 2011)
73. Puthanakit, T.; Oberdorfer, P.M.; Akarathum, N.; Wannarit, P.; Sirisanthana, T.; Sirisanthana, V. Immune Reconstitution Syndrome After Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Thai Children. Pediatr. Infect. Dis. J., 2006, 25, 53-8.
74. Donald, P.R.; van Helden, P.D. The global burden of tuberculosis--combating drug resistance in difficult times. N. Engl. J. Med., 2009, 360, 2393-2395.
75. Schaaf, H.S.; Marais, B.J.; Hesseling, A.C.; Gie, R.P.; Beyers, N.; Donald, P.R. Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatr., 2006, 95, 523-528.
76. Schaaf, H.S.; Marais B.J.; Hesseling, A.C.; Brittle, W.; Donald, P.R.; Surveillance of Antituberculosis Drug Resistance Among Children From the Western Cape Province of South Africa--An Upward Trend. Am. J. Public Health, 2009, 99, 1486-1490.
77. Marais, B.J.; Victor, T.C.; Hesseling, A.C.; Barnard, M.; Jordaan, A.; Brittle, W.; Reuter, H.; Beyers, N.; van Helden, P.D.; Warren, R.M.; Schaaf, H.S. Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J. Clin. Microbiol., 2006, 44, 3539-3543.
78. LoBue, P.A.; Moser, K.S. Isoniazid-and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002. Int. J. Tuberc. Lung Dis., 2005, 9, 501-506.
79. Schaaf, H.S.; Victor, T.C.; Engelke, E.; Brittle, W.; Marais, B.J.; Hesseling, A.C.; van Helden, P.D.; Donald, P.R. Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur. J. Clin. Microbiol. Infect. Dis., 2007, 26, 203-205.
80. Moulding, T.S. Should Isoniazid be used in retreatment of tuberculosis despite acquired Isoniazid resistance? Am. Rev. Respir Dis., 1981, 123, 262-264.
81. Warren, R.M.; Streicher, E.M.; Gey van Pittius, N.C.; van der Spuy, G.D.; Marais, B.J.; Victor, T.C.; Sirgel, F.; Donald, P.R.; van Helden, P.D. The clinical relevance of mycobacterial pharmacogentics. Tuberculosis, 2009, 89, 199-202.
82. Katiyar, S.K.; Bihari, S.; Prakash, S.; Mamtani, M.; Kulkarni, H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis., 2008, 12, 139-145.
83. Ziakas, P.D.; Mylonakis, E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection, a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin. Infect. Dis., 2009, 15, 1883-1889.
84. th edition 2009, 680-698.
85. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO Reports, [Online] 2008 http,//www.who.int/tb/publications/2008/who_htm_tb_2008_402_exec_summ.pdf (Accessed January 17, 2011).
86. Schaaf, H.S.; Gie, R.P.; Kennedy, M.; Beyers, N.; Hesseling, P.B.; Donald, P.R. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis, a 30-month follow-up. Pediatrics, 2002, 109, 765-771.
87. Schaaf, H.S. Drug-resistant tuberculosis in children. S. Afr. Med. J., 2007, 97(Part 2), 995-997.
88. Bonilla, C.A.; Crossa, A.; Jave, H.O.; Mitnick, C.D.; Jamanca, R.B.; Herrera, C.; Asencios, L.; Mendoza, A.; Bayona, J.; Zignol, M.; Jaramillo, E. Management of extensively drug-resistant tuberculosis in Peru, cure is possible. PLos One, 2008, 3, e2957.
89. Ghandi, N.R.; Moll, A.; Sturm, A.W.; Pawinski, R.; Govender, T.; Lalloo, U.; Zeller, K.; Andrews, J.; Friedland, G. Extensively drugresistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area in South Africa. Lancet, 2006, 368, 1575-1580.
90. Schaaf, H.S.; Willemse, M.; Donald, P.R. Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis. Pediatr. Infect. Dis. J., 2009, 28, 748-750.
91. Ma, Z.; Lienhardt, C. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin. Chest Med., 2009, 30, 755-768.
92. Chang, K.C.; Leung, C.C.; Yew, W.W.; Lau, T.Y.; Leung, W.M.; Tam, C.M.; Lam, H.C.; Tse, P.S.; Wong, M.Y.; Lee, S.N.; Wat, K.I.; Ma, Y.H. Newer fluoroquinolones for treating respiratory infection, do they mask tuberculosis? Eur. Respir. J., 2010, 35, 606-613.
93. Ziganshina, L.E.; Squire, S.B. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst. Rev., 2008, 23, (1), CD004795.
94. Rustomjee, R.; Lienhardt, C.; Kanyok, T.; Davies, G.R.; Levin, J.; Mthiyane, T.; Reddy, C.; Sturm, A.W.; Sirgel, F.A.; Allen, J.; Coleman, D.J.; Fourie, B.; Mitchison, D.A.; Gatifloxacin for TB (OFLOTUB) study team. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung. Dis., 2008, 12, 128-138.
95. Alffenaar, J.W.; van Altena, R.; Bökkerink, H.J.; Luijckx, G.J.; van Soolingen, D.; Aarnoutse, R.E.; van der Werf, T.S. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin. Infect. Dis., 2009, 49, 1080-1082.
96. Park-Wyllie, L.Y.; Juurlink, D.N.; Kopp, A.; Shah, B.R.; Stukel, T.A.; Stumpo, C.; Dresser, L.; Low, D.E.; Mamdani, M.M. Outpatient gatifloxacin therapy and dysglycemia in older adults. N. Engl. J. Med., 2006, 354, 1352-1361.
97. Nuermberger, E.; Tyagi, S.; Tasneen, R.; Williams, K.N.; Almeida, D.; Rosenthal, I.; Grosset, J.H. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother., 2008, 52, 1522-1524.
98. Burman, W.J.; Goldberg, S.; Johnson, J.L.; Muzanye, G.; Engle, M.; Mosher, A.W.; Choudhri, S.; Daley, C.L.; Munsiff, S.S.; Zhao, Z.; Vernon, A.; Chaisson, R.E. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med., 2006, 174, 331-338.
99. Conde MB, Efron A, Loredo C, De Souza GR, Graça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis, a double-blind, randomised, controlled phase II trial. Lancet, 2009, 373, 1183-1189.
100. Wang, J.Y.; Wang, J.T.; Tsai, T.H.; Hsu, C.L.; Yu, C.J.; Hsueh, P.R.; Lee, L.N.; Yang, P.C. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis., 2010, 14, 65-71.
101. Dorman, S.E.; Johnson, J.L.; Goldberg, S.; Muzanye, G.; Padayatchi, N.; Bozeman, L.; Heilig, C.M.; Bernardo, J.; Choudhri, S.; Grosset, J.H.; Guy, E.; Guyadeen, P.; Leus, M.C.; Maltas, G.; Menzies, D.; Nuermberger, E.L.; Villarino, M.; Vernon, A.; Chaisson, R.E. Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med., 2009, 180, 273-280.
102. Haagsma, A.C.; Ibrahim, R.A.; Wagner, M.J.; Krab, K.; Vergauwen, K.; Guillemont, J.; Andries, K.; Lill, H.; Koul, A.; Bald, D. Selectivity of TMC207 toward mycobacterial ATP synthetase as compared to eucariotic homologue. Antimicrob Agents Chemother., 2009, 53(3), 1290-1292.
103. Ibrahim, M.; Truffot-Pernot, C.; Andries, K.; Jarlier, V.; Veziris, N. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am. J. Respir. Crit. Care Med., 2009, 180, 553-557.
104. Rustomjee, R.; Diacon, A.H.; Allen, J.; Venter, A.; Reddy, C.; Patientia, R.F.; Mthiyane, T.C.; De Marez, T.; van Heeswijk, R.; Kerstens, R.; Koul, A.; De Beule, K.; Donald, P.R.; McNeeley, D.F. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother., 2008, 53, 2831-2835.
105. Diacon, A.H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee, R.; Page-Shipp, L.; Pistorius, C.; Krause, R.; Bogoshi, M.; Churchyard, G.; Venter, A.; Allen, J.; Palomino, J.C.; De Marez, T.; van Heeswijk, R.P.; Lounis, N.; Meyvisch, P.; Verbeeck, J.; Parys, W.; de Beule, K.; Andries, K.; McNeeley, D.F. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med., 2009, 360, 2397-2405.
106. Hu, Y.; Coates, A.R.; Mitchison, D.A. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis., 2008, 12, 69-73.
107. Saliu, O.Y.; Crismale, C.; Schander, S.K.; Wallis, R.S. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J Antimicrob. Chemother., 2007, 60, 994-998.
108. Singh, R.; Manjunatha, U.; Boshoff, H.I.; Ha, Y.H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C.S.; Lee, I.Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T.H.; Jiricek, J.; Barry, C.E. 3rd. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science, 2008, 322, 1392-1395.
109. The tuberculosis trials consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients, a randomized controlled trial. Lancet, 2002, 360, 528-534.
110. Rosenthal, I.M.; Zhang, M.; Williams, K.N.; Peloquin, C.A.; Tyagi, S.; Vernon, A.A.; Bishai, W.R.; Chaisson, R.E.; Grosset, J.H.; Nuermberger, E.L. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med., 2007, 4, e344.
111. Nikoneneko, B.V.; Protopopova, M.; Samala, R.; Einck, L.; Nacy, C.A. Drug therapy for experimental tuberculosis (TB), improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother., 2007, 51, 1563-1565.
112. Williams, K.N.; Brickner, S.J.; Stover, C.K.; Zhu, T.; Ogden, A.; Tasneen, R.; Tyagi, S.; Grosset, J.H, Nuermberger, E.L. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am. J. Respir. Crit. Care Med., 2009, 180, 371-376.
113. Burman W.J.; Cotton, M.F.; Gibb, D.M.; Walker, A.S.; Vernon, A.A.; Donald, P.R. Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med., 2008, 5, e176.
114. Chintu, C.; Luo, C.; Bhat, G.; Raviglione, M.; DuPont, H.; Zumla, A. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I. Arch. Dis. Child, 1993, 68, 665-668